ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/bispecific-T-cell-engager-CD19-targeting
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/bispecific-T-cell-engager-CD19-targeting
10
trial(s) found.
NCT07519772
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma (
WaveSpan-008
)
bispecific T-cell engager,CD19-targeting
Lymphoma
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4812 - Townsville - Townsville University Hospital
NCT07509151
Haem
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (
SOUNDTRACK-C1
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6168 - Cooloongup - Rockingham Hospital
NCT07215585
Haem
Phase 3
Recruiting
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (
SOUNDTRACK-D2
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06526793
Haem
Phase 2
Recruiting
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (
SOUNDTRACK-B
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
Non-Hodgkin's lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06137118
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06124157
Paed
Phase 2
Recruiting
An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Christchurch Children's Hospital
NCT04546399
Haem
Phase 2
Recruiting
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse (
NCI-2020-06813
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
+ bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Leukaemia
Mixed phenotype acute leukaemia
NSW
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (10)
Recruitment Country and State
VIC (8)
WA (8)
NSW (6)
QLD (5)
SA (3)
NZ (2)
TAS (1)
Phase
Phase 1 / Phase 2 (3)
Phase 2 (3)
Phase 3 (4)
Trial Type
Haem (7)
Paed (3)
Cancer Therapy Class
CD19
100%
BTK
10%
CD20
10%
BCR-ABL1
10%
KIT
10%
PDGFRA
10%
SRC
10%
YES1
10%
PD-1
10%
PD-1/PD-L1
10%
CD22
10%
Facility
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
2305 - New Lambton Heights - John Hunter Children's Hospital (4)
4101 - South Brisbane - Queensland Children's Hospital (4)
6009 - Perth - Perth Children's Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2145 - Westmead - The Children's Hospital at Westmead (3)
2109 - North Ryde - Macquarie University Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3168 - Clayton - Monash Medical Centre (2)
2031 - Randwick - Sydney Children's Hospital (2)
3052 - Parkville - Royal Children's Hospital Melbourne (2)
NZ.1023 - Grafton - Starship Children's Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4812 - Townsville - Townsville University Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6000 - Perth - Royal Perth Hospital (1)
6168 - Cooloongup - Rockingham Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3004 - Melbourne, Southbank - Alfred Health (1)
2217 - Kogarah - St George Hospital (1)
3168 - Clayton - Monash Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
NZ.8011 - Christchurch - Christchurch Children's Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Lymphoid leukaemia
Lymphoma
Acute lymphoblastic leukaemia
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Mixed phenotype acute leukaemia
Mantle cell lymphoma
Follicular lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy